• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up1.22% Nasdaq Up2.00%

    Ultragenyx Pharmaceutical Inc. (RARE)

    -NasdaqGS
    68.28 Up 3.09(4.74%) May 24, 4:00PM EDT
    ProfileGet Profile for:
    Ultragenyx Pharmaceutical Inc.
    60 Leveroni Court
    Novato, CA 94949
    United States - Map
    Phone: 415-483-8800
    Fax: 415-483-8810
    Website: http://www.ultragenyx.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Biotechnology
    Full Time Employees:289

    Business Summary 

    Ultragenyx Pharmaceutical Inc., a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. The company is developing various biologics product candidates, including KRN23, a human monoclonal antibody in Phase III adult study to bind and reduce the biological activity of fibroblast growth factor 23 to enhance abnormally low phosphate levels in patients with X-linked hypophosphatemia, as well as for the treatment of adult inoperable tumor-induced osteomalacia patients. Its biologics product candidates also comprise recombinant human beta-glucuronidase (rhGUS), an intravenous enzyme replacement therapy, which completed the Phase 3 clinical study for the treatment of mucopolysaccharidosis 7; and recombinant human protective protein cathepsin-A (rhPPCA), an enzyme replacement therapy in preclinical development for galactosialidosis. In addition, the company is developing a range of small-molecule product candidates comprising UX007, a substrate replacement therapy in a Phase II study for patients with fatty acid oxidation disorders, as well as for patients with glucose transporter type-1 deficiency syndrome; and aceneuramic acid extended-release (Ace-ER), an oral formulation of sialic acid in a Phase II extension study to treat hereditary inclusion body myopathy. It has collaboration and license agreement with Nobelpharma Co., Ltd., Kyowa Hakko Kirin Co. Ltd., and Nobelpharma Co., Ltd.; and license agreements with Saint Louis University, AAI Pharma Services Corp., HIBM Research Group, St. Jude Children’s Research Hospital, and Baylor Research Institute. Ultragenyx Pharmaceutical Inc. was founded in 2010 and is headquartered in Novato, California.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Ultragenyx Pharmaceutical Inc.

    Corporate Governance 
    Ultragenyx Pharmaceutical Inc.’s ISS Governance QuickScore as of May 1, 2016 is 8. The pillar scores are Audit: 2; Board: 5; Shareholder Rights: 8; Compensation: 9.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
     PayExercised
    Dr. Emil D. Kakkis M.D., Ph.D., 56
    Chief Exec. Officer, Pres and Director
    854.00K0.00
    Ms. Shalini Sharp , 41
    Chief Financial Officer and Sr. VP
    630.00K0.00
    Mr. Dennis Karl Huang , 51
    Chief Technical Operations Officer and Sr. VP
    331.00K0.00
    Mr. John Richard Pinion II, 50
    Chief Quality Operations Officer and Sr. VP of Analytical Sciences & Research
    262.00K0.00
    Dr. Jayson Donald Alexander Dallas M.D., 48
    Chief Commercial Officer and Sr. VP
    379.00K0.00
    Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders